- Home
- VMO vs IRWD Comparison
VMO vs IRWD Comparison
Compare VMO & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMO | IRWD |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.0M | 687.4M |
| IPO Year | 1994 | 2009 |
Fundamental Metrics
Financial Performance| Metric | VMO | IRWD |
|---|---|---|
| Price | $8.50 | $3.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.10 |
| AVG Volume (30 Days) | 470.5K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $59.19 |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | ★ N/A | $6.83 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $8.12 | $1.41 |
| 52 Week High | $10.10 | $5.78 |
Technical Indicators
Market Signals| Indicator | VMO | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 45.63 |
| Support Level | $8.12 | $3.89 |
| Resistance Level | $9.83 | $3.96 |
| Average True Range (ATR) | 0.19 | 0.20 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 33.61 | 36.49 |
Price Performance
Historical ComparisonAbout VMO Invesco Municipal Opportunity Trust
Invesco Municipal Opportunity Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide common shareholders with a high level of current income exempt from federal income tax, consistent with preservation of capital.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.